Brought to you by 
Public offering nets $48.6mm for Argos
29 Jul 2016
Executive Summary
Argos Therapeutics Inc. (immunotherapies for cancer and HIV infection) netted $48.6mm through the public sale of 9.1mm common shares at $5.50. Investors also received five-year warrants to buy 6.8mm shares at $5.50. Some of the proceeds will fund the Phase III ADAPT trial with lead candidate AGS003 for metastatic renal cell carcinoma (mRCC) and a Phase II study of the same compound for early RCC and other solid tumors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $48.6mm for Argos
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice